JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on July 18, 2006; DOI: 10.1124/jpet.106.106823


0022-3565/06/3191-386-395$20.00
JPET 319:386-395, 2006
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.106.106823v1
319/1/386    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tawfik, H. E.
Right arrow Articles by Caldwell, R. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tawfik, H. E.
Right arrow Articles by Caldwell, R. W.

CARDIOVASCULAR

Simvastatin Improves Diabetes-Induced Coronary Endothelial Dysfunction

Huda E. Tawfik, Azza B. El-Remessy, Suraporn Matragoon, Guochuan Ma, Ruth B. Caldwell, and R. William Caldwell

Department of Pharmacology & Toxicology (H.E.T., A.B.E., S.M., G.M., R.B.C., R.W.C.) and Vascular Biology Center (R.B.C.), Medical College of Georgia Augusta, Georgia

3-Hydroxy-3-methylglutaryl CoA reductase inhibitors decrease cardiovascular morbidity in diabetic patients, but the mechanism is unclear. We studied the actions of simvastatin (SIM) in enhancing NO bioavailability and reducing oxidative stress in coronary vessels from diabetic rats and in rat coronary artery endothelial cells (RCAEC) exposed to high glucose. Coronary arteries isolated from diabetic rats showed decreases in acetylcholine (ACh)-mediated maximal relaxation from 81.0 ± 4.5% in controls to 43.5 ± 7.6% at 4 weeks and 22.3 ± 0.6% at 10 weeks of diabetes. This effect was associated with oxidative stress in coronary vessels as shown by dichlorofluorescein (DCF) imaging and nitrotyrosine labeling. Diabetes also reduced trans-coronary uptake of [3H]L-arginine. Supplemental L-arginine (50 mg/kg/day p.o.) did not improve coronary vasorelaxation to ACh. However, SIM treatment (5 mg/kg/day subcutaneously) improved maximal ACh relaxation to 65.8 ± 5.1% at 4 weeks and 47.1 ± 3.9% at 10 weeks. Coronary arteries from rats treated with both SIM and L-arginine demonstrated the same maximal relaxation to ACh (66.1 ± 3%) as SIM alone. Mevalonate and L-NAME (N{omega}-nitro-L-arginine methyl ester hydrochloride) inhibited the response to ACh in SIM-treated diabetic rats. Coronary arteries from all groups relaxed similarly to sodium nitroprusside. SIM increased endothelial NO synthase protein levels and blocked diabetes-induced increases in DCF and nitrotyrosine labeling in diabetic coronary vessels. SIM treatment restored normal NO levels in media from high-glucose-treated RCAEC and plasma of diabetic rat. Treatment with SIM or the NADPH oxidase inhibitor apocynin also blocked high-glucose-induced increases in reactive oxygen species and superoxide formation in RCAEC. Taken together, these data suggest that SIM improves diabetes-induced coronary dysfunction by reducing oxidative stress and increasing NO bioavailability.


Received April 25, 2006; accepted July 7, 2006.

Address correspondence to: Dr. R. William Caldwell, Pharmacology and Toxicology, Medical College of Georgia, 1120 15th Street, CB-3624, Augusta, GA 30912. E-mail: wcaldwel{at}mail.mcg.edu




This article has been cited by other articles:


Home page
HypertensionHome page
A. M. Briones, N. Rodriguez-Criado, R. Hernanz, A. B. Garcia-Redondo, R. R. Rodrigues-Diez, M. J. Alonso, J. Egido, M. Ruiz-Ortega, and M. Salaices
Atorvastatin Prevents Angiotensin II-Induced Vascular Remodeling and Oxidative Stress
Hypertension, July 1, 2009; 54(1): 142 - 149.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
R. Arita, Y. Hata, S. Nakao, T. Kita, M. Miura, S. Kawahara, S. Zandi, L. Almulki, F. Tayyari, H. Shimokawa, et al.
Rho Kinase Inhibition by Fasudil Ameliorates Diabetes-Induced Microvascular Damage
Diabetes, January 1, 2009; 58(1): 215 - 226.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
H. E. Tawfik, J. Cena, R. Schulz, and S. Kaufman
Role of oxidative stress in multiparity-induced endothelial dysfunction
Am J Physiol Heart Circ Physiol, October 1, 2008; 295(4): H1736 - H1742.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
M. Al-Shabrawey, M. Bartoli, A. B. El-Remessy, G. Ma, S. Matragoon, T. Lemtalsi, R. W. Caldwell, and R. B. Caldwell
Role of NADPH Oxidase and Stat3 in Statin-Mediated Protection against Diabetic Retinopathy
Invest. Ophthalmol. Vis. Sci., July 1, 2008; 49(7): 3231 - 3238.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
T. Nagaoka, L. Kuo, Y. Ren, A. Yoshida, and T. W. Hein
C-Reactive Protein Inhibits Endothelium-Dependent Nitric Oxide-Mediated Dilation of Retinal Arterioles via Enhanced Superoxide Production
Invest. Ophthalmol. Vis. Sci., May 1, 2008; 49(5): 2053 - 2060.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
G. Spinetti, N. Kraenkel, C. Emanueli, and P. Madeddu
Diabetes and vessel wall remodelling: from mechanistic insights to regenerative therapies
Cardiovasc Res, May 1, 2008; 78(2): 265 - 273.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
M. J. Romero, D. H. Platt, H. E. Tawfik, M. Labazi, A. B. El-Remessy, M. Bartoli, R. B. Caldwell, and R. W. Caldwell
Diabetes-induced Coronary Vascular Dysfunction Involves Increased Arginase Activity
Circ. Res., January 4, 2008; 102(1): 95 - 102.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics.